<DOC>
	<DOCNO>NCT00407563</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness tolerability combination bevacizumab Abraxane treatment woman epithelial ovarian cancer peritoneal cancer . The study also evaluate patient 's quality life treatment .</brief_summary>
	<brief_title>Bevacizumab With Abraxane Patients With Recurrent Ovarian/ Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Measurable disease CT MRI . At least 1 `` target lesion '' use assess response define GOG RECIST criterion . ECOG performance status 0 1 . Patient provide voluntary write informed consent . At least 18 year age . Negative serum pregnancy test . Recovered recent surgery least 30 day free active infection . Received follow prior therapy time enrollment : Must 1 prior platinumbased chemotherapeutic regimen contain carboplatin , cisplatin organoplatinum . Initial therapy may include highdose therapy , consolidation , extend therapy . Patient define recurrent progression disease within 6 month last platinum chemotherapy . May 1 additional cytotoxic noncytotoxic chemotherapy regimen . Must adequate hematologic hepatic function . Previously receive bevacizumab . History invasive malignancy exception nonmelanoma skin cancer . ECOG performance status 2 , 3 , 4 . Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Genentechsponsored bevacizumab cancer study . Patient must bevacizumab naïve . Blood pressure &gt; 150/100 mm Hg antihypertensive medication . Prior history hypertensive crisis hypertensive encephalopathy . Diagnosed unstable angina per NYHA Grade 2 great congestive heart failure . History myocardial infarction within 6 month enrollment . History stroke transient ischemic attack within 6 month prior study enrollment . Clinically significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) symptomatic peripheral vascular disease . Bleeding diathesis coagulopathy . Presence CNS brain metastasis . Preexisting peripheral neuropathy Grade ≥ 2 . A major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study . A partial complete small large bowel obstruction demonstrate radiologically within 3 month prior study enrollment . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment . Positive pregnancy test lactating . History abdominal fistula , GI perforation , intraabdominal abscess within 6 month prior study enrollment . Serious , nonhealing wound , ulcer , bone fracture . Serious intercurrent medical psychiatric illness , include serious active infection . Inability comply study and/or followup procedure . Life expectancy le 12 week . Proteinuria screen demonstrate either : Urine protein : creatinine ( UPC ) ratio ≥ 1.0 screening OR Urine dipstick proteinuria ≥ 2+ ( patient discover ≥2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Known hypersensitivity component bevacizumab .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>